No published randomized trial has tested whether 0.25 mg of semaglutide holds a maintenance result, and when a Harvard endocrinologist reviewed the trend this year, the verdict was blunt: no legitimate long-term data, and no agreed definition of what microdosing even is
Currently available GLP-1 receptor agonists include shorter-acting formulations such as exenatide (administered twice daily), daily options like liraglutide, and longer-acting agents like semaglutide and dulaglutide (weekly injections)
[1] [2] It has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and is therefore not an approved medicine available through standard NHS prescribing channels
Metformin-induced autophagy and irisin improves INS-1 cell function and survival in high-glucose environment via AMPK/SIRT1/PGC-1 signal pathway
Natural interventions such as quercetin, coenzyme Q10, magnesium, and bioactive whey peptides, along with dietary and lifestyle changes, can help lower blood pressure
Some patients may benefit from additional supportive options, but these should always be discussed before starting them